Geode Capital Management
LBRX

Geode Capital Management’s LB Pharmaceuticals LBRX Stock Holding History

Geode Capital Management’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.9M Buy
612,793
+94,565
+18% +$2.78M ﹤0.01% 2156
2026
Q1 		$12.8M Buy
518,228
+76,774
+17% +$1.77M ﹤0.01% 2242
2025
Q4 		$9.83M Buy
441,454
+427,863
+3,148% +$7.47M ﹤0.01% 2425
2025
Q3 		$215K Buy
+13,591
New +$216K ﹤0.01% 3902

Other funds holding LBRX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Geode Capital Management's LBRX Position: Q2 2026 in Review

Geode Capital Management increased its LB Pharmaceuticals (LBRX) stake by 18% in Q2 2026, buying an estimated $2.78M and bringing the position to 612,793 shares worth $19.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2156.

Geode Capital Management first reported a position in LBRX in Q3 2025 and has held it in 4 quarters since. 115 funds tracked by Wall St. Rank hold LBRX as of Q2 2026.

  • Geode Capital Management held 612,793 shares of LB Pharmaceuticals worth $19.9M as of Q2 2026.
  • Geode Capital Management bought 94,565 LB Pharmaceuticals shares in Q2 2026, an estimated $2.78M.
  • LB Pharmaceuticals made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2156 holding.
  • Geode Capital Management first reported a position in LB Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 115 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.